Jeliazkova P, Umgelter A, Braren R, et al. - Given that most patients with hepatocellular carcinoma are diagnosed at intermediate or advanced stages (BCLC B or C) and undergo palliative local treatments like transarterial chemoembolization or selective internal radiation therapy, also called radioembolization, researchers conducted this retrospective study to analyze prognostic factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization and radioembolization. All hepatocellular carcinoma patients who had transarterial chemoembolization between January 2010 and December 2014 as well as all hepatocellular carcinoma patients who had selective internal radiation therapy between August 2012 and December 2016 were recruited. One hundred twenty-nine patients in the transarterial chemoembolization group and 34 patients in the selective internal radiation therapy group were registered. Although hepatic dysfunction tests predicted survival in both cohorts similarly, the authors found tumor size to predict survival differently in patients treated with transarterial chemoembolization and selective internal radiation therapy. Tumor size can aid in selecting the most suitable treatment in patients with hepatocellular carcinoma, although this finding needs to be confirmed in further studies.